These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 29462023)

  • 1. Advocating the Development of Next-Generation High-Relaxivity Gadolinium Chelates for Clinical Magnetic Resonance.
    Runge VM; Heverhagen JT
    Invest Radiol; 2018 Jul; 53(7):381-389. PubMed ID: 29462023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dechelation (Transmetalation): Consequences and Safety Concerns With the Linear Gadolinium-Based Contrast Agents, In View of Recent Health Care Rulings by the EMA (Europe), FDA (United States), and PMDA (Japan).
    Runge VM
    Invest Radiol; 2018 Oct; 53(10):571-578. PubMed ID: 30130320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain tumor enhancement in magnetic resonance imaging at 3 tesla: intraindividual comparison of two high relaxivity macromolecular contrast media with a standard extracellular gd-chelate in a rat brain tumor model.
    Fries P; Runge VM; Bücker A; Schürholz H; Reith W; Robert P; Jackson C; Lanz T; Schneider G
    Invest Radiol; 2009 Apr; 44(4):200-6. PubMed ID: 19300099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
    Runge VM
    Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
    Fretellier N; Salhi M; Schroeder J; Siegmund H; Chevalier T; Bruneval P; Jestin-Mayer G; Delaloge F; Factor C; Mayer JF; Fabicki JM; Robic C; Bonnemain B; Idée JM; Corot C
    Eur J Pharm Sci; 2015 May; 72():46-56. PubMed ID: 25736527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Gadolinium Concentrations within Multiple Rat Organs after Intravenous Administration of Linear versus Macrocyclic Gadolinium Chelates.
    McDonald RJ; McDonald JS; Dai D; Schroeder D; Jentoft ME; Murray DL; Kadirvel R; Eckel LJ; Kallmes DF
    Radiology; 2017 Nov; 285(2):536-545. PubMed ID: 28640692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium Complex of 1,4,7,10-Tetraazacyclododecane-1,4,7-trisacetic Acid (DO3A)-Ethoxybenzyl (EOB) Conjugate as a New Macrocyclic Hepatobiliary MRI Contrast Agent.
    Baek AR; Kim HK; Park S; Lee GH; Kang HJ; Jung JC; Park JS; Ryeom HK; Kim TJ; Chang Y
    J Med Chem; 2017 Jun; 60(12):4861-4868. PubMed ID: 28530407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
    Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
    Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus.
    Runge VM
    Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion.
    Lancelot E
    Invest Radiol; 2016 Nov; 51(11):691-700. PubMed ID: 27175546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macrocyclic and Other Non-Group 1 Gadolinium Contrast Agents Deposit Low Levels of Gadolinium in Brain and Bone Tissue: Preliminary Results From 9 Patients With Normal Renal Function.
    Murata N; Gonzalez-Cuyar LF; Murata K; Fligner C; Dills R; Hippe D; Maravilla KR
    Invest Radiol; 2016 Jul; 51(7):447-53. PubMed ID: 26863577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity.
    Robic C; Port M; Rousseaux O; Louguet S; Fretellier N; Catoen S; Factor C; Le Greneur S; Medina C; Bourrinet P; Raynal I; Idée JM; Corot C
    Invest Radiol; 2019 Aug; 54(8):475-484. PubMed ID: 30973459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current uses of gadolinium chelates for clinical magnetic resonance imaging examination of the liver.
    Low RN
    Top Magn Reson Imaging; 1998 Jun; 9(3):141-66. PubMed ID: 9621404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gadolinium-based magnetic resonance contrast agents for neuroradiology: an overview.
    Kanal E
    Magn Reson Imaging Clin N Am; 2012 Nov; 20(4):625-31. PubMed ID: 23088942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging.
    Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV
    Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retention of gadolinium compounds used in magnetic resonance imaging: a critical review and the recommendations of regulatory agencies.
    Martí-Bonmatí L; Martí-Bonmatí E
    Radiologia; 2017; 59(6):469-477. PubMed ID: 29110904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gold nanoparticles functionalised with fast water exchanging Gd3+ chelates: linker effects on the relaxivity.
    Ferreira MF; Gonçalves J; Mousavi B; Prata MI; Rodrigues SP; Calle D; López-Larrubia P; Cerdan S; Rodrigues TB; Ferreira PM; Helm L; Martins JA; Geraldes CF
    Dalton Trans; 2015 Mar; 44(9):4016-31. PubMed ID: 25611006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing lesions of the brain: intraindividual crossover comparison of contrast enhancement after gadobenate dimeglumine versus established gadolinium comparators.
    Essig M; Tartaro A; Tartaglione T; Pirovano G; Kirchin MA; Spinazzi A
    Acad Radiol; 2006 Jun; 13(6):744-51. PubMed ID: 16679277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.